is jardiance a glp 1 drug Eli Lilly, Boehringer hit FDA roadblock in quest to repurpose for Type diabetes Jardiance®

In a 10-week clinical trial, a daily dose of 20 mg oral semaglutide achieved a steady-state plasma concentration of 30 nM, and when daily dose of oral semaglutide was increased to 40 mg, the semaglutide plasma concentration reached about 60 nM (102), which was over a thousand times higher than the EC50 of semaglutide for GLP-1R activation (95)

Ozempic, on the other hand, is only a GLP-1 receptor agonist

Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action

27 Subsequently, they investigated a triple agonist capable of simultaneously targeting the GLP-1R, the GCGR, and the GIPR

Natriuresis and osmotic diuresis: reduces blood volume and cardiac/renal stress

While oral formulations are emerging, injectable solutions continue to lead due to their established clinical success in managing blood glucose levels, providing healthcare providers with reliable options for managing T2DM and obesity in patients requiring stable, consistent dosing